News › Industry News, Patient Care

Novo Nordisk Halts Wegovy Sales on Hims & Hers, Claiming “Deceptive Marketing” Practices

June 25, 2025

Novo Nordisk terminates its collaboration with Hims & Hers Health, Inc. due to concerns about deceptive marketing and allegations of selling illegitimate, knockoff versions of the pharmaceutical firm’s weight-loss drug, Wegovy.

“After over one month into the collaboration, Hims & Hers Health, Inc. has failed to adhere to the law which prohibits mass sales of compounded drugs under the false guise of ‘personalization’ and are disseminating deceptive marketing that put patient safety at risk,” a Novo Nordisk spokesperson told CBS MoneyWatch. “This is unacceptable, and that is why we have decided to end the collaboration.”

Read more at CBS News >>

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • Compounded Tirzepatide, NAD+ Injections Recalled Nationwide Over Sterility Concerns
    • Meliora Consulting Becomes Silver Vendor Affiliate with the American Med Spa Association
    • FDA Sends Peptide ‘Interim Access Policy’ to White House for Review
    • New ACOG Menopause Guidelines Expand Hormone Therapy and Symptom Treatment Recommendations
    • Galderma to Acquire ZO Skin Health for $1.5 Billion
Advertisement